The European Commission published a draft report on the first authorization for a health claim made on a combination product referring to the reduction of disease risk (14.1 health claim). In 2013, EFSA had already issued a positive opinion on this health claim. Now, 5 years later, the EC Commission finally agrees.
The health claim is related to the combination of artichoke leaf dry extract standardized in caffeoylquinic acids, monacolin K in red yeast rice, sugar-cane derived policosanols, procyanidolic oligomers (OPC) from French maritime pine bark, garlic dry extract standardised in allicin, d-α-tocopheryl hydrogen succinate, riboflavin, and inositol hexanicotinate and the reduction of blood LDL-cholesterol concentrations. This claim was submitted by Laboratoire Lescuyer (France) on Limicol®.
Limicol® is now the first food supplement with data protection for a claim relating to the reduction in a risk factor for a disease. As of the European Commission’s final approval, Laboratoire LESCUYER will thus be the only company able to make that health claim for its exclusive and patented formula for 5 years.
The claim conditions are:
“Only for food supplements which provide 600 mg artichoke leaf dry extract with 30-36 mg caffeoylquinic acids, 500 mg red yeast rice with 2 mg monacolin K, 10 mg sugarcane derived policosanols, 20 mg French maritime pine bark extract with 18 mg procyanidolic oligomers (OPC), 30 mg garlic dry extract with 0.25 mg allicin, 30 mg α-tocopherol equivalents, 5 mg riboflavin and 9 mg inositol hexanicotinate divided in three daily doses to be consumed with the major meals”